Filing Details
- Accession Number:
- 0001144204-17-031786
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-06-08 18:38:38
- Reporting Period:
- 2017-06-08
- Filing Date:
- 2017-06-08
- Accepted Time:
- 2017-06-08 18:38:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1175151 | Cytosorbents Corp | CTSO | Surgical & Medical Instruments & Apparatus (3841) | 980373793 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1368151 | Vincent Capponi | C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-06-08 | 2,500 | $4.00 | 275,062 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- Includes (i) the following restricted stock units ("RSUs") that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, and (c) 125,000 RSUs granted on April 8, 2015, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 35,938 RSUs granted on February 24, 2017 and (b) 23,000 RSUs granted on June 7, 2016 and (iii) 19,224 shares of common stock owned by the reporting person (including 2,500 shares of common stock purchased in the open market on June 8, 2017 and reported on this Form 4).